# Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-the-bofa-securities-2026-healthcare-conference
Ticker: SANA
Company: Sana Biotechnology
Source: Sana Biotechnology
Published: 2026-05-05 20:05 EST
Original Source URL: https://ir.sana.com
## Summary

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2026 Healthcare Conference at 2:20 p.m.

## Article Body
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2026 Healthcare Conference at 2:20 p.m.
## Recent Company News
- 2026-05-27 20:05 EST — [Sana Biotechnology to Present at June 2026 Investor Conferences](https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-june-2026-investor-conferences) — Source: Sana Biotechnology
- 2026-05-15 13:00 EST — [Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-sale-of-approximately-69-million-of-shares-through-its-at-the-market-atm-facility) — Source: Sana Biotechnology
- 2026-05-12 20:05 EST — [Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs](https://biopharmsignal.com/news/SANA/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-sg293-surrogate-demonstrating-cell-specific-delivery-potent-car-t-cell-generation-and-deep-b-cell-depletion-in-nhps) — Source: Sana Biotechnology
- 2026-05-11 20:05 EST — [Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/SANA/sana-biotechnology-reports-first-quarter-2026-financial-results-and-business-updates) — Source: Sana Biotechnology
- 2026-05-05 20:05 EST — [Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference](https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-the-bofa-securities-2026-healthcare-conference) — Source: Sana Biotechnology
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)